9HN-28559-10628
2 vaccinations
1 coded response
18 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 840 / UT
- Registered
- 2021-01-12
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-01-12
Registered in v-safe
-
2021-01-12
Dose 1 — Pfizer-BioNTech
- 2021-01-12
- 2021-01-13
- 2021-01-14
- 2021-01-15
- 2021-01-16
- 2021-01-17
- 2021-01-18
- 2021-01-19
- 2021-01-26
-
2021-02-02
Dose 2 — Pfizer-BioNTech
- 2021-02-09
- 2021-02-16
- 2021-02-23
- 2021-03-02
- 2021-03-09
- 2021-03-16
- 2021-05-04
- 2021-08-03
-
2022-02-02
Survey response — 12 months, dose 2MedDRA: Cough, Diarrhoea, Dyspnoea, Headache, Oropharyngeal pain, Pain, Respiratory tract congestion, Rhinorrhoea — Feeling: Fair · Be unable to work or attend schoolFree text: Shortness of breath, headache, diarrhea, body aches, congestion, cough, runny nose, and sore throat.MedDRA releases: 2024-11 · check-in free text available
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-01-12 | Pfizer-BioNTech | |
| 2 | 2021-02-02 | Pfizer-BioNTech |
Free text
Release 11 — 12 months, dose 2
Symptoms: Shortness of breath, headache, diarrhea, body aches, congestion, cough, runny nose, and sore throat.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Cough | · | · | ✓ |
| SD | Diarrhoea | · | · | ✓ |
| SD | Dyspnoea | · | · | ✓ |
| SD | Headache | · | · | ✓ |
| SD | Oropharyngeal pain | · | · | ✓ |
| SD | Pain | · | · | ✓ |
| SD | Respiratory tract congestion | · | · | ✓ |
| SD | Rhinorrhoea | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release